LETTER TO THE EDITOR
Breast disease I read with interest the review by Mike Baum of the ABC <if BreastDiseases, edited by Michael Dixon. ' Professor Baum claims that the authors are very good at emphasising surrogate end points, saying that "of course screen detected cancers have a longer survival rate" and that this could be explained by lead time. This is a rather surprising statement, as I can find no reference to longer survival rates in the whole of the article,
The review is also factually incorrect to suggest that only one in four or one in five cases of duct carcinoma in situ progress to invasive disease in the woman's lifetime. If Professor Baum had read the section within this book on duct carcinoma in situ by David Page, the world's leading authority on this topic, he would have noted that the invasive risk for low grade duct carcinoma in situ (cases missed by pathologists) is one in three. Over 50'X, of cases of duct carcinoma in situ detected by screening are of the high grade comedo type. ' The only study on the invasive potential of this subgroup of duct carcinoma in situ suggests a 75% invasive rate with a mean interval to invasion offour years. I Given these facts, detecting duct carcinoma in situ at screening would appear to be a particularly beneficial aspect of screening. AJ EVANS Consultant radiologist .'·411; 011(11 Breast S, ; n:c.'"i1lK Training Ccntn: CilyH", pil, , 1 H"..k""IIR, , , , d "', , , , i 
